SCHEMBL3410877

SCHEMBL3410877

Cc1cc(O)c(C(=O)CCc2ccc3c(c2)CCO3)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC5A1 P13866 9/20 0.51
▸ SLC5A2 P31639 9/20 0.51
▸ CTSB P07858 1/20 0.51
▸ CYP19A1 P11511 3/20 0.46
▸ TYR P14679 1/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ GAA P10253 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ NFKB1 P19838 2/20 0.45
▸ NFKB2 Q00653 2/20 0.45
▸ RELA Q04206 2/20 0.45
▸ POLB P06746 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ SLC16A3 O15427 1/20 0.45
▸ TTR P02766 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3413671 0.82 SLC5A1 (0.58) SLC5A1SLC5A2CTSBCYP19A1TYR
SCHEMBL1405119 0.79 RAB9A (0.50) RAB9ALMNAPOLBMAPTKDM4E
SCHEMBL27605521 0.79 RAB9A (0.51) RAB9APOLBMAPTNPC1CTNNB1
SCHEMBL13553029 0.78 SLC5A2 (0.72) SLC5A1SLC5A2HPGDHSD17B10MAPT
SCHEMBL12808194 0.78 SLC5A2 (0.45) SLC5A1SLC5A2CTSBCYP19A1RAB9A
SCHEMBL13553026 0.78 SLC5A2 (0.56) SLC5A1SLC5A2SLC28A3
SCHEMBL81136 0.77 FABP4 (0.58) RAB9APOLBTSHRNPC1CTNNB1
SCHEMBL18007683 0.76 RAB9A (0.49) RAB9APOLBMAPTNPC1CTNNB1
SCHEMBL338133 0.76 CYP4F2 (0.51) RAB9APOLBTP53NPC1CHRM4
SCHEMBL18306234 0.75 SLC5A1 (0.84) SLC5A1SLC5A2CYP19A1TYRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816331-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA NV (BE) 2010-10-19 — — US disclosed
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES PATEL MONA 2010-03-11 — — US disclosed
EP-1680414-A4 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 — — EP disclosed
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES PATEL MONA 2009-04-16 — — US disclosed
US-7511021-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 — — US disclosed
US-20060217323-A1 Substituted indazole-O-glucosides Tanabe Pharma Corporation (JP) 2006-09-28 — — US disclosed
US-7084124-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-01 — — US disclosed
EP-1680414-A2 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-19 — — EP disclosed
US-20050032711-A1 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — US disclosed
WO-2005011592-A2 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032711-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 SLC5A1 9/4885SLC5A2 10/4885CTSB 4365/4885
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES GYS2, GPR119, UGGT1 SLC5A1 9/4885SLC5A2 10/4885CTSB 4365/4885
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES GYS2, GPR119, PYGL SLC5A1 11/4885SLC5A2 10/4885CTSB 4179/4885
US-20060217323-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 SLC5A1 9/4885SLC5A2 10/4885CTSB 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback